HER-2

ERBB2

A gene on chromosome 17q11.2-q12 that encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. ERBB2 has no ligand-binding domain and thus cannot bind growth factors; it does, however, bind to other ligand-bound EGF receptor family members, forming a heterodimer, stabilising ligand binding and enhancing kinase-mediated activation of downstream signalling pathways (e.g., those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase).

Molecular pathology
ERBB2 amplification and overexpression commonly occurs in breast and ovarian cancers.

HER-2

c-erbB-2, HER-2/neu Oncology An erbB family oncogene related to epidermal growth factor; HER-2 overexpression, espceically breast CA, and stomach CAs, which have a ↓ survival and ↓ time to relapse. See Breast cancer.
References in periodicals archive ?
Release date- 29082019 - Melbourne - Starpharma today announced that treatment with a novel HER-2 Targeted DEP conjugate from its internal Targeted DEP program resulted in tumour regression and 100% survival in a preclinical human ovarian cancer model.
HER-2 receptor expression was analyzed through immuno-histochemical (IHC) and fluorescence in situ hybridization method (FISH/SISH).
This researcher decided to pit the oils against each other for treating a form of breast cancer called HER-2. HER-2 is very aggressive.
For example, some cancer treatments, such as HER-2 targeted therapies, can cause weakening of the heart muscle, a condition known as heart failure.
Therefore, HER-3 dimerizes with other ErbB receptors, specifically with HER-2 to become activated (l0).
Abbott will provide ANGLE with its proprietary PathVysion HER-2 DNA FISH Probe kits for its ANG-002 US Food & Drug Administration (FDA) study for FISH (fluorescence in situ hybridisation) analysis of circulating tumour cells (CTCs) in the form of a research grant.
The study involved feeding the different types of omega-3s to mice with a highly aggressive form of human breast cancer called HER-2. HER-2 affects 25per cent of women and has a poor prognosis.
Increasing evidence suggests an improved prognosis in these cancers when therapy is targeted towards the biomarker, human epidermal growth factor receptor-2 (HER-2) [5].
The molecular genetic subtypes of luminal A, luminal B, HER-2, and normal breast-like and basal-like type were identified by gene profiling analysis [4-6].
Hear more from Alison at the Antibodies & Antibody Drug Conjugates conference this April 2018, as she presents the Opening Address; "Use of modelling and simulation to compare new generation HER-2 ADCs with Kadcyla[TM]: a focus on PK and efficacy."